SV investment has resulted in the approval of 24 novel therapeutics
SV News
12 October 2023Portfolio NewsMestag Therapeutics announces the appointment of expert advisors Dr. Cassandra Choe-Juliak, Dr. Greg Elson and Samantha Vieira MBA
10 October 2023Portfolio NewsAviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations
9 October 2023Portfolio NewsAstronauTx closes a £48 million ($61 million) Series A financing to create new treatments for Alzheimer’s disease- 8 October 2023Portfolio NewsUK biotech group raises £48mn for Alzheimer’s research
5 October 2023Portfolio NewsSean M. Healey & AMG Center for ALS awarded NIH U01 Grant to support Expanded Access to Pridopidine in Collaboration with Prilenia Therapeutics
29 September 2023SV NewsThe Guardian: Pioneering a new era for dementia care
27 September 2023Portfolio NewsSitryx raises additional $39 million to progress development of disease-modifying therapeutics for chronic autoimmune and inflammatory diseases
6 September 2023Portfolio NewsNimbus is back for more, raising $210M to fuel pipeline seven months after $4B Takeda deal- 6 September 2023Portfolio NewsNimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines
3 September 2023Portfolio NewsBritish biotech faces a funding battle in race with the US
28 August 2023Portfolio NewsFierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023
16 August 2023Portfolio NewsImbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
